IP Library Granted Patent US 8,168,636
Granted Patent B2
US 8,168,636 · App. 12/986,951 · Granted May 1, 2012

Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,168,636
App. No.
12/986,951
Granted
May 1, 2012
Kind
B2
Abstract

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

Claims (9)

1. A compound which is 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N 3 -(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine, as a free base, a pharmaceutically acceptable salt thereof or an N-oxide thereof.

2. The compound of claim 1 which is the free base.

3. The compound of claim 1 which is a pharmaceutically acceptable salt of 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N 3 -(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine.

4. A compound which is 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N 3 -(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine, as a free base, a pharmaceutically acceptable salt thereof or an N-oxide thereof.

5. The compound of claim 4 which is the free base.

6. The compound of claim 4 which is a pharmaceutically acceptable salt of 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N 3 -(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine.

7. The compound of claim 3 or claim 6 wherein the pharmaceutically acceptable salt is a pharmaceutically acceptable acid addition salt.

8. The compound of claim 7 wherein the acid is selected from formic acid, trifluoroacetic acid, hydrochloric acid, benzenesulfonic acid or acetic acid.

9. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 1 , as a free base, a pharmaceutically acceptable salt thereof or an N-oxide thereof, or comprising a pharmaceutically acceptable excipient and a compound of claim 4 , as a free base, a pharmaceutically acceptable salt thereof or an N-oxide thereof.

Assignments (2)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →